FGFR2 and intrahepatic cholangiocarcinoma: Almost all the attempts aim to inhibit activation of FGFR2, and our findings of that SPRY2 antagonizes FGFR2 signalling in ICC could bring a new insight to the emerging therapy besides the FGFR2 inhibitor.